The groundbreaking success of Sildenafil undeniably reshaped the drug landscape, but investing in companies heavily reliant on generic versions presents a challenging picture. While early profits were substantial, the expiration of patents and the rise of less expensive alternatives have eroded market share. Therefore, a thorough Pharma analysis of